Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2024 · 10-Q
Revenue$41.53M$41.53M+57.5% vs Q2 2023 Net Income-$51.91M-$51.91MN/M vs Q2 2023 EPS Diluted-$2.88-$2.88N/M vs Q2 2023 Operating Income-$19,100,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$12,906,000N/M Margins · derivedOperating margin-46.0%−38.5 pt vs Q2 2023
Net margin-125.0%−133.7 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 7, 2024 · 38 d after period end